PEREGRINE RADIATION THERAPY DOSE CALCULATION SYSTEM

K993675 · Nomos Corp. · MUJ · Sep 5, 2000 · Radiology

Device Facts

Record IDK993675
Device NamePEREGRINE RADIATION THERAPY DOSE CALCULATION SYSTEM
ApplicantNomos Corp.
Product CodeMUJ · Radiology
Decision DateSep 5, 2000
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 892.5050
Device ClassClass 2
AttributesSoftware as a Medical Device

Intended Use

The PEREGRINE Radiation Therapy Dose Calculation System is intended to be used for radiation therapy in conjunction with a Radiation Treatment Planning system to calculate dose distributions. It is to be used by the physician and/or other competent health professional for clinical review and judgement of radiation treatment plans. The goal of the protections is to produce consistent highly accurate dose calculations using the Monte Carlo algorithms.

Device Story

PEREGRINE is a 3-D Monte Carlo radiation transport system for radiation therapy treatment planning. It models accelerator beam production, beam modifiers, and radiation transport within patient heterogeneities. The system operates on standard computer microprocessors and integrates with commercial radiation treatment planning systems. It is used by radiation oncologists, medical physicists, therapists, or dosimetrists in clinical settings to generate accurate dose distributions. Healthcare providers use these outputs to review and judge treatment plans before patient irradiation. By providing high-resolution, accurate dose calculations, the device assists in optimizing radiation delivery, potentially improving treatment precision and patient outcomes.

Clinical Evidence

Bench testing only. Verification and validation were performed using a comprehensive set of clinical measurements designed to stress physics algorithms across a range of materials, densities, and beam energies (open, blocked, wedged, and compensated fields). Testing included simple phantoms and phantoms with surface/sub-surface heterogeneities. Hazard analysis and design reviews were conducted to ensure safety and effectiveness.

Technological Characteristics

3-D Monte Carlo radiation transport system. Interfaces with radiation treatment planning systems via industry standard protocols. Operates on commercial computer microprocessors. Developed under formal design controls and quality system regulations.

Indications for Use

Indicated for use by radiation oncologists, medical physicists, radiation therapists, or dosimetrists to calculate dose distributions for radiation therapy treatments employing radiation sources and beam modifiers, for clinical review and judgement prior to patient treatment.

Regulatory Classification

Identification

A medical charged-particle radiation therapy system is a device that produces by acceleration high energy charged particles (e.g., electrons and protons) intended for use in radiation therapy. This generic type of device may include signal analysis and display equipment, patient and equipment supports, treatment planning computer programs, component parts, and accessories.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ K993675 Page 1 of 2 ## Tab 2 510(k) Summary of Safety and Effectiveness PEREGRINE™ Radiation Therapy Dose Calculation System Pursuant to Section 513(l) of the Federal food, Drug, and Cosmetic Act and 21 CFR 807.92: NOMOS Corporation | (a) (1) Submitter's address: | 2591 Wexford Bayne Road<br>Sewickley, PA 15143 | |---------------------------------------|----------------------------------------------------------------| | (a) (1) Submitter's telephone number: | (724) 934-8200 | | (a) (1) Contact person: | William O. Chishko<br>Director, Quality and Regulatory Affairs | | (a) (1) Date summary was prepared: | October 26, 1999 | | (a) (2) Trade or proprietary name: | PEREGRINE™ Radiation Therapy Dose Calculation<br>System | | (a) (2) Common or usual name: | Radiation Therapy Dose Calculation System | | (a) (2) Classification name: | Accelerator, Linear, Medical, Accessory | ADAC Laboratories Pinnacle3 3D Treatment K926008 Planning Throughput (a) (4) Device description: (a) (3) Predicate device: (a) (1) Submitter's name: The PEREGRINE Radiation Therapy Dose Calculation System is a 3-D Monte Carlo radiation transport system designed to provide accurate dose calculations for radiation therapy treatment planning. PEREGRINE combines Monte Carlo-based modeling of the accelerator beam production system, Monte Carlo simulation of treatment-specific beam modifiers and Monte Carlo transport in the patient to provide a robust and accurate representation of the radiation source, beam modifiers and heterogeneities in the patient. PEREGRINE has been designed to provide highly accurate, high resolution radiation dose calculations rapidly on economical, commercially available computer microprocessors and to be easily integrated with commercial radiation treatment planning systems. In order to ensure its accuracy, PEREGRINE has been verified against a comprehensive set of clinical measurements designed to stress the physics algorithms for a full range of clinically relevant materials, densities and beam energies for open, blocked, wedged and compensated fields incident on both simple phantoms and phantoms with a variety of surface and sub-surface heterogeneities. 90 IYE [21 CFR 892.5050] {1}------------------------------------------------ K993675 Page 2 of 2 (a) (5) Intended use: The PEREGRINE Radiation Therapy Dose Calculation System is intended to be used for radiation therapy in conjunction with a Radiation Treatment Planning system to calculate dose distributions. It is to be used by the physician and/or other competent health aooo alombation clinical review and judgement of radiation treatment plans. The goal of the protections is to produce consistent highly accurate dose calculations using the Monte Carlo algorithms. (a) (6) Technological characteristics: The PEREGRINE Radiation Therapy Dose Calculation System is designed to interface to radiation treatment planning systems using industry standard protocols. It was developed and tested using Quality system design control and product release procedures. (b) (1) Non-clinical tests submitted: The PEREGRINE Radiation Therapy Dose Calculation System was developed and tested using the design controls set forth in the NOMOS Corporation Quality System. Some aortions of the system were developed and tested at Lawrence Livermore National Laboratories using design controls set forth in Lawrence Livermore National Laboratories Quality System. This system was audited by NOMOS and found to be compliant with the requirements of the NOMOS Quality System as well as the regulatory requirements of the FDA Quality System Regulations and EC Medical Device Directive. It has a product specification, which was used as the basis for the development of verification and validation plans, tests and acceptance criteria. A rigorous hazard analysis also was performed, which includes mitigation for each identified hazard. Verification and validation tests were completed in accordance with the test plans. They prove that the PEREGRINE Radiation Therapy Dose Calculation System meets the design criteria and user needs. Design reviews were conducted at appropriate stages of development. (b) (3) Test Conclusions: Validation and verification testing of the PEREGRINE Radiation Therapy Dose Calculation System demonstrate that the software is safe and effective. Test completion shows that the device performs and is substantially equivalent to the predicate system for those features for which this submission is being made as well as overall performance. Product release also is made in accordance with established NOMOS Corporation Quality System Procedures after all tests are completed, reviewed and meet acceptance criteria and regulatory requirements. {2}------------------------------------------------ ## DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 P = 5 2000 Francis X. Dobscha Director of Quality and Regulatory Affairs NOMOS Corporation 2591 Wexford Bayne Road Sewickley, PA 15143 Re: K993675 Peregrine™ Radiation Therapy Dose Calculation System Dated: July 11, 2000 Received: July 13, 2000 Regulatory Class: II 21 CFR 892.5050/Procode: 90 MUJ Dear Mr. Dobscha: We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have decemined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations. This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro , diagnostic devices), please contact the Office of Compliance at (301) 594-4639. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrfvdsma/dsmamain.html". Sincerely yours, Daniel C. Schultz, M.D. Daniel G. Schultz, M.D. Captain, USPHS Acting Director, Division of Reproductive, Abdominal, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure (s) {3}------------------------------------------------ Page 1 of 1 993675 510(k) Number [if known]: Device Name: PEREGRINE™ Radiation Therapy Dose Calculation System Indication for Use: The PEREGRINE™ Radiation Therapy Dose Calculation System is used in conjunction with a radiation treatment planning system to provide the dose distribution for radiation therapy treatments employing radiation sources and associated beam modifiers for clinical review and judgement prior to treating the patient. The PEREGRINE™ Radiation Therapy Dose Calculation System is intended to be used by a competent health professional such as a radiation oncologist, medical physicist, radiation therapist, or dosimetrist. ## ISE DO NOT WRITE BELOW THIS LINE. CONTINUE ON ANOTHER PAGE AS NEEDED] Concurrence of the CDRH Office of Device Evaluation [ODE] Prescription Use (Per 21 CFR 801.109) OR Over the Counter Use (Optional Format , 2 January 1996 David A. Severson (Division Sign-Off) Division of Reproductive, Abdominal, ENT, and Radiological Devices 510(k) Number_1
Innolitics

Panel 1

/
Sort by
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...